SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) today announced five data presentations
will be delivered at the upcoming American Association for Cancer
Research (AACR) Annual Meeting, which will be held April 1-5, 2017 at the Walter E. Washington
Convention Center in Washington,
D.C. Researchers will present new preclinical data on
NKTR-214, the Company's immuno-stimulatory CD122-biased agonist, as
well as on NKTR-255, the Company's IL-15 therapeutic candidate.
Details of the poster presentations are as follows:
Abstract 1598/Poster 6: "Single agent NKTR-214, a biased
IL2 pathway agonist, increases immune cell infiltrates in brain
tumors and prolongs survival in rodent (rattus) glioblastoma
(GBM)"
Session: Cytokines: The First Modern
Immunotherapies
Date and Time: Monday, April 3, 2017,
8:00 AM - 12:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26
Abstract 1603/Poster 11: "NKTR-255 engages the IL-15 pathway
driving CD8 T cell survival and CD8 memory T cell
proliferation"
Session: Cytokines: The First Modern Immunotherapies
Date and Time: Monday, April 3, 2017,
8:00 AM – 12:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26
Abstract 1604/Poster 12: "NKTR-214 Synergizes with
Radiotherapy to Drive Tumor Regression"
Session: Cytokines:
The First Modern Immunotherapies
Date and Time: Monday, April 3, 2017,
8:00 AM – 12:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26
Abstract 1617/Poster 25: "Mechanistic modeling of a new
kinetically-controlled CD122 agonist for cancer immunotherapy:
NKTR-214 pharmacokinetics, pharmacodynamics, and receptor
pharmacology"
Session: Cytokines: The First Modern Immunotherapies
Date and Time: Monday, April 3, 2017,
8:00 AM – 12:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26
Abstract 2671/Poster 30: "Antitumor activity of NKTR-214 in
combination with Adopted Cell Transfer (ACT) in an aggressive
murine melanoma"
Session: Immune Response to Hematopoietic Tumors: New Development
in Tumor Immunology
Date and Time: Monday, April 3, 2017
1:00 PM – 5:00
PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage
biopharmaceutical company whose mission is to discover and develop
innovative medicines to address the unmet medical needs of
patients. Our R&D pipeline of new investigational medicines
includes treatments for cancer, auto-immune disease and chronic
pain. We leverage Nektar's proprietary and proven chemistry
platform in the discovery and design of our new therapeutic
candidates. Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama
and Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
Contact:
For Investors:
Jennifer Ruddock of Nektar
Therapeutics
415-482-5585
Jodi Sievers of Nektar
Therapeutics
415-482-5593
For Media:
Dan Budwick of Pure
Communications
973-271-6085
dan@purecommunications.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-announces-upcoming-presentations-at-the-american-association-for-cancer-research-annual-meeting-300416349.html
SOURCE Nektar Therapeutics